Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Axovant Sciences (AXON): Reiterating Sell - Chardan
-
HealthEquity to Present at Conferences in September
-
Atlantic Acquisition Corp. Announces that Common Stock and Rights to Commence Separate Trading on or about September 7, 2017
-
Regenxbio Inc. (RGNX) PT Raised to $75 at Chardan Capital Markets
-
Iovanace Biotherapeutics (IOVA): Fast Track Status Validates Regulatory Path - Chardan
-
Nightstar Files Registration Statement For Proposed Initial Public Offering
-
Kamada Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Pre-Open Movers 08/29: (MOV) (CTLT) (IMGN) Higher; (FINL) (ACOR) (JILL) Lower (more...)
-
Chardan Capital Markets Downgrades Intellia Therapeutics (NTLA) to Neutral
-
Chardan Capital Markets Starts Tivity Health (TVTY) at Neutral
-
I-AM Capital Acquisition Company Completes $50 Million Initial Public Offering
-
I-AM Capital Acquisition Company Announces Pricing of $50,000,000 Initial Public Offering
-
miRagen Therapeutics (MGEN) PT Raised to $29 at Chardan Capital Markets
-
Chardan Capital Markets Starts Foresight Autonomous ADS (FRSX) at Buy
-
AveXis (AVXS): 3 Catalysts, Raising PT To $135 - Chardan
-
Akari Therapeutcis (AKTX): Skeptical Of Coversin In PNH - Chardan
-
Amicus Therapeutics (FOLD): Raising PT to $17.50 - Chardan
-
Alnylam Pharma (ALNY): Cutting PT to $124 - Chardan
-
Editas Medicine Announces Second Quarter 2017 Results and Update
-
Atlantic Acquisition Corp. Announces Pricing of $40,000,000 Initial Public Offering
-
Vuzix Corp. (VUZI) Announces $8.63M Common Stock Offering
-
Vuzix Announces $8,625,000 Common Stock Offering
-
Pensare Acquisition Corp. Common Stock, Warrants and Rights to Commence Trading Separately on August 8, 2017
-
Chardan Capital Markets Downgrades Benefitfocus (BNFT) to Neutral
-
Pensare Acquisition Corp. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option; Raises $310.5 Million
-
UPDATE: Chardan Capital Markets Upgrades Spark Therapeutics (ONCE) to Buy
-
Intellia Therapeutics (NTLA): Raising PT - Chardan
-
Chardan Capital Markets Downgrades Regulus Therapeutics (RGLS) to Neutral
-
Kamada (KMDA) Prices 3.33M Public Offering at $4.50/Ordinary Share
-
Kamada Announces Pricing of Public Offering of Ordinary Shares
-
Kamada (KMDA) Proposed Public Offering of Ordinary Shares
-
Kamada Announces Proposed Public Offering of Ordinary Shares
-
Pensare Acquisition Corp. (WRLSU) Prices 27M Share IPO at $10/Sh
-
Pensare Acquisition Corp. Announces Pricing of $270 Million Initial Public Offering
-
StreetInsider.com Premium Hot Research Recap 7/25
-
Chardan Capital Markets Starts miRagen Therapeutics (MGEN) at Buy
-
First Harvest Engages Hayden IR and Slee 3 Consulting to Develop Comprehensive Investor Relations Program
-
Bison Capital Acquisition Corp. Ordinary Shares, Warrants and Rights to Commence Trading Separately on or About July 17, 2017
-
PlacementTracker Publishes First Half 2017 PIPE Market League Tables
-
Chardan Capital Markets Starts Tabula Rasa Healthcare (TRHC) at Buy
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $131 at Chardan Capital Markets
-
AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
KBL Merger Corp. IV Announces Closing of Underwriters' Over-Allotment Option in Full in Connection with its Initial Public Offering and Separate Trading of its Common Stock, Rights and Warrants, Comme
-
Constellation Alpha Capital Corp. Completes Initial Public Offering
-
Spring Bank Pharmaceuticals (SBPH) Prices 2.88M Common Stock Offering at $13/Share
-
Spring Bank Pharmaceuticals Prices $37.5 Million Public Offering of Common Stock
-
AveXis (AVXS) Prices 3.75M Shares Offering; Net Proceeds Expected to be Roughly $234.5M
-
AveXis Announces Pricing of Public Offering of Common Stock
-
Constellation Alpha Capital Corp. (CNACU) Prices 12.5M Share IPO at $10/Sh
-
Teladoc (TDOC) PT Raised to $41 at Chardan Capital Markets; Bullish on Best Doctors Deal

